Quince Therapeutics Stock Quote QNCX - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

1.8122

Bid

1.81

Ask

1.90

Volume

76,562

1.75 Day's Range 1.95

0.5116 52 Week Range 2.45

Market Cap

79.74M

Previous Close

1.93

Open

1.8858

Last Trade

1.8101

Last Trade Time

13:07:31

Financial Volume

$ 142,268

VWAP

1.8582

Average Volume (3m)

619,250

Shares Outstanding

44,001,643

Dividend Yield

PE Ratio

-2.73

Earnings Per Share (EPS)

-0.71

Revenue

Net Profit

-31.39M

Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug ... Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

quincetx.com

Headquarters

Wilmington, Delaware, USA

Founded

Quince Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker QNCX. The last closing price for Quince Therapeutics was $1.93. Over the last year, Quince Therapeutics shares have traded in a share price range of $ 0.5116 to $ 2.45.

Quince Therapeutics currently has 44,001,643 shares outstanding. The market capitalization of Quince Therapeutics is $84.92 million. Quince Therapeutics has a price to earnings ratio (PE ratio) of -2.73.

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

Form SC 13D - General Statement of Acquisition of Beneficial Ownership

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Phase 3 NEAT clinical trial on track with 32 patients enrolled to date with majority of U.S. and European study sites now enrolling patients Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage...

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the...

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the...

Quince Therapeutics to Participate at Upcoming Investor Conferences

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.1078	-5.61458333333	1.92	1.9594	1.65	172536	1.79874248	CS
4	-0.1978	-9.8407960199	2.01	2.45	1.65	222156	1.93236603	CS
12	1.0522	138.447368421	0.76	2.45	0.69	619250	1.44470069	CS
26	1.1122	158.885714286	0.7	2.45	0.5116	367928	1.26222128	CS
52	0.7622	72.5904761905	1.05	2.45	0.5116	229880	1.21804877	CS
156	-10.9278	-85.7755102041	12.74	13.7	0.5116	466354	2.33713371	CS
260	-58.1078	-96.9756341789	59.92	121.98	0.5116	458507	13.42994165	CS

QNCX - Frequently Asked Questions (FAQ)

What is the current Quince Therapeutics share price?

The current share price of Quince Therapeutics is $ 1.8122

How many Quince Therapeutics shares are in issue?

Quince Therapeutics has 44,001,643 shares in issue

What is the market cap of Quince Therapeutics?

The market capitalisation of Quince Therapeutics is USD 84.92M

What is the 1 year trading range for Quince Therapeutics share price?

Quince Therapeutics has traded in the range of $ 0.5116 to $ 2.45 during the past year

What is the PE ratio of Quince Therapeutics?

The price to earnings ratio of Quince Therapeutics is -2.73

What is the reporting currency for Quince Therapeutics?

Quince Therapeutics reports financial results in USD

What is the latest annual profit for Quince Therapeutics?

The latest annual profit of Quince Therapeutics is USD -31.39M

What is the registered address of Quince Therapeutics?

The registered address for Quince Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Quince Therapeutics website address?

The website address for Quince Therapeutics is quincetx.com

Which industry sector does Quince Therapeutics operate in?

Quince Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NXUNXU Inc	$ 1.74 (614.87%)	491.21M
WATTEnergous Corporation	$ 1.425 (246.55%)	170.53M
INTZIntrusion Inc	$ 5.1435 (138.13%)	119.31M
SMXSMX Security Matters Public Company	$ 0.7833 (121.52%)	239.02M
CYNCYNGN Inc	$ 1.285 (104.65%)	66.84M
ABPAbpro Holdings Inc	$ 2.17 (-51.67%)	1.58M
TRAWTraws Pharma Inc	$ 8.19 (-38.97%)	930.34k
SHOTWSafety Shot Inc	$ 0.13 (-27.90%)	1.25k
LITMSnow Lake Resources Ltd	$ 1.155 (-27.81%)	46.42M
DOMHDominari Holdings Inc	$ 0.843 (-26.70%)	134.38k
NXUNXU Inc	$ 1.74 (614.87%)	494.59M
VINCVincerx Inc	$ 0.3439 (77.27%)	312.66M
SMXSMX Security Matters Public Company	$ 0.7833 (121.52%)	239.64M
XTIAXTI Aerospace Inc	$ 0.04 (1.27%)	200.6M
WATTEnergous Corporation	$ 1.425 (246.55%)	171.27M